Scleral growth stunting via sub-Tenon injection of cross-linking solutions in live rabbits

• Published in: British journal of ophthalmology Vol. 107; no. 6; p. 889
• Main Authors: Hoang, Quan V, Wen, Quan, Paik, David C, Chun, Yong Yao, Silverman, Ronald, Nagasaki, Takayuki, Trokel, Stephen L, Zyablitskaya, Mariya
• Format: Journal Article
• Language: English
• Published: England 01-06-2023
• Subjects: Animals; Cross-Linking Reagents - pharmacology; Disease Models, Animal; Injections; Myopia, Degenerative; Rabbits; Sclera; eye (globe); sclera and episclera
• ISSN: 1468-2079
• DOI: 10.1136/bjophthalmol-2021-319427

Scleral cross-linking is a potential method to inhibit axial elongation of the eye, preventing the progression of pathological myopia. Formaldehyde releasers, which are common preservatives found in cosmetics and ophthalmic solutions, have been shown to be not only effective in cross-linking corneal collagen in vitro and in vivo, but also have minimal toxicity effects on the eye. The present study aims to evaluate the efficacy of scleral cross-linking using sodium hydroxymethylglycinate (SMG) to inhibit eye growth using an in vivo rabbit model.
A cross-linking solution containing 40 mM SMG was delivered to the sub-Tenon's space behind the equator. The application regimen included a two-quadrant injection performed five times over 2 weeks on New Zealand White rabbits (n=5, group 1), and one-time injection followed for up to 5 days on Dutch-Belted rabbits (n=6, group 2). Group 1 was monitored serially for axial length changes using B-scan ultrasound for 5-6 weeks. Group 2 was injected with a higher viscosity solution formulation. Both groups were evaluated for thermal denaturation temperature changes of the sclera postmortem.
Axial growth was limited by 10%-20% following SMG treatment as compared with the untreated eye. Thermal denaturation analysis showed increased heat resistance of the treated eyes in the areas of injection. Overall, the SMG treatment inhibited eye growth with few side effects from the injections.
Cross-linking solutions delivered via sub-Tenon injection provide a potential method for limiting axial length growth in progressive myopia and could be used as a potential treatment for myopia.